Board of Directors

MDIC’s Board of Directors consists of world-class representatives from the medical device industry, government, and patient groups who work together to advance the mission of the consortium

Peter J. Arduini | Integra LifeSciences

President and CEO and Director

Peter J. Arduini
Peter J. Arduini is Integra LifeSciences’ President and Chief Executive Officer and a Director. Integra, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. Mr. Arduini joined Integra in November 2010 as President and Chief Operating Officer and was appointed Chief Executive Officer and a Director in January 2012. Before joining Integra, Mr. Arduini was Corporate Vice President and President of Medication Delivery, Baxter Healthcare, which he joined in 2005. Mr. Arduini was responsible for a $4.8 billion global division of Baxter. Prior to joining Baxter, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses. Prior to joining General Electric Healthcare, he spent four years with Procter and Gamble in sales and marketing. Mr. Arduini serves on the Board of Directors of ADVAMED, the Advanced Medical Technology Association, and the Board of Directors of the National Italian American Foundation. Mr. Arduini received his Bachelor’s Degree in Marketing from Susquehanna University and a Master’s in Management from Northwestern University’s Kellogg School of Management.

Mark D. Carlson, MD | Abbott

Division Vice President and Chief Medical Officer

Mark D. Carlson, M.D.
Mark Carlson is Division Vice President and Chief Medical Officer at Abbott. In this capacity, Dr. Carlson leads a medical affairs organization that serves medical device divisions of Abbott Medical. Dr. Carlson joined Abbot in January, 2017 when the company acquired St. Jude Medical. St. Jude Medical. He joined St. Jude Medical in November 2006, serving as Chief Medical Officer and Senior Vice President, Research and Clinical Affairs, in the St. Jude Medical Implantable Electronic Systems Division until September, 2013 and as Vice President, Global Clinical Affairs and Chief Medical Officer until Abbott acquired the company.

Dr. Carlson received his M.D. from the University of Kansas, a Masters degree in public policy from Duke University, and a B.S. from Kansas State University. He trained in internal medicine at University Hospitals of Cleveland and Case Western Reserve University and in cardiology and cardiac electrophysiology at the Massachusetts General Hospital and Harvard University. He joined the faculty of Case Western Reserve University in 1988 and remains on faculty as adjunct professor of medicine. His research on arrhythmias and neural control has resulted in over 150 publications. As a Robert Wood Johnson Fellow on Senator Orrin Hatch’s Senate Judiciary Committee, Dr. Carlson worked on the Medicare Prescription Drug, Improvement and Modernization Act and the Cord Blood Stem Cell Act. Thereafter, he returned to Case as associate vice president, government relations. Dr. Carlson served on the FDA’s Devices Dispute Resolution Panel, the NCDR ICD registry steering committee, and chaired the HRS Health Policy Committee, the ACC Electrophysiology Committee, the HRS/FDA Policy Conference on Device Performance, and the HRS task force on device performance policies and guidelines and the Medicare Evidence Development & Coverage Advisory Committee. He is a member of the board of directors of the Medical Device Innovation Consortium.

Dr. Carlson is a member of the board and past President of the West Los Angeles County Council of the Boy Scouts of America, and a member of the Dean’s Advisory Council at Kansas State University.

Allan Coukell | The Pew Charitable Trusts

Director of Drugs and Medical Devices

MDIC Board Vice Chair

Allan-CoukellAllan Coukell is Senior Director of Drugs and Medical Devices at the Pew Charitable Trusts, an independent nonprofit research and public policy organization, where he oversees initiatives related to drug and medical device innovation and safety, medical conflicts of interest, the pharmaceutical supply chain, and the FDA. Prior to joining Pew, he practiced as a clinical pharmacist in oncology at the London Health Sciences Center and Ontario Regional Cancer Center; served as a senior medical writer and editor with the medical journal publisher Adis International; and covered health and science as a reporter and producer for WBUR (NPR) in Boston and Radio New Zealand. He served previously as consumer representative on the FDA’s Cardiovascular and Renal Drugs Advisory Committee.

Steve Ferguson | Cook Group Incorporated

Chairman of the Board

Steve Ferguson serves as Chairman of the Board of Cook Group Incorporated, the parent company of Cook companies worldwide involved in the research, development, manufacture and the sale of medical devices. Since 1963 Cook Group companies have been combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. Cook Group companies employ more than 12,000 people globally with operations in North America, Europe and Asia-Pacific. Today, Cook manufactures more than 16,000 products that serve more than 40 medical specialties in 135 countries.

Steve Ferguson served four terms in the Indiana House of Representatives from 1967 to 1974. He is active in a number of university, community, state, and national organizations, including: Medical Technology Leadership Forum, Indiana Health Industry Forum, Indiana Chamber of Commerce, Central Indiana Corporate Partnership, Regenstrief Foundation, and The Center for Human Growth. He served on the Indiana Education Roundtable and is a former member and past Chairman of the State of Indiana Commission for Higher Education (1992-98). In 1998, he was appointed to the Indiana University Board of Trustees by Governor Frank O’Bannon, was re-appointed to the Board by Governor Joe Kernan in 2004,and by Governor Mitch Daniels in 2007 and 2009, serving as President of the Board for three years. Mr. Ferguson received his A.B. from Wabash College in 1963 and a J.D. with distinction from Indiana University School of Law in 1966.

Rachael L. Fleurence, PhD | Patient-Centered Outcomes Research Institute (PCORI)

Program Director

She joined PCORI in April 2012. She leads PCORI’s initiative to build the National Patient-Centered Clinical Research Network, or PCORnet, a transformational effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United-States. In this capacity, she chairs the PCORnet Executive Council and co-chairs the PCORnet Council. PCORnet is a 330 million dollar investment involving 130 health institutions across the country and 20 patient powered research networks. Dr Fleurence is currently serving on the National Medical Device Evaluation System Planning Board. A health economist and health services researcher by training, Dr Fleurence previously worked in the private sector outcomes research. Dr Fleurence received a BA from Cambridge University (United-Kingdom), a MA in business management from ESSEC-Paris (France), and a MSc and PhD in health economics from the University of York (United-Kingdom).

Rick Geoffrion | Mitralign, Inc.

President and CEO

PhotographerMr. Geoffrion currently serves as the President and Chief Executive Officer of Mitralign, a venture-backed private company that has developed a transcatheter platform for mitral and tricuspid valve repair.
He has over 30 years of management experience in the medical device industry and more than 25 years in the cardiovascular device space. A co-founder of Mitralign, he previously led the company foundation and served as the early stage CEO for three additional medical device companies (CircuLite, FlowMedica, X-Cell). He also guided the recapitalization and redirection of two successful medical device companies (Impella, Pathway). Mr. Geoffrion has also served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc. He holds a BSME and an MBA from the University of Connecticut.

 

Chip Hance | Creganna Medical

CEO

PhotographerChip Hance is CEO of Creganna Medical, an Ireland based supplier to the minimally invasive medical device industry.  With more than 2,000 employees in six locations (Ireland, Minnesota, Northern California, Portland, Costa Rica and Singapore), Creganna focuses on manufacturing and design of delivery system components and subassemblies for OEM manufacturers in interventional cardiology, structural heart, peripheral vascular, electrophysiology, endoscopy and other minimally invasive fields.

In 2012-13, Hance was an Entrepreneur-in-Residence at CDRH within the FDA.  He co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.

Prior to his FDA experience, Hance was most recently President of Abbott Vascular, the cardiovascular device division of Abbott. Over a decade in interventional cardiology at Abbott Vascular, Hance led the organization to global leadership in the drug-eluting stent market through the launch of Xience in the U.S., Japan and China.  Hance also led the development and CE marking of Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the acquisition and international expansion of Mitraclip, a percutaneous mitral valve repair device.

Hance earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.

 

William A. Hawkins III | Retired Chairman and CEO Medtronic


William-HawkinsBill Hawkins is a Senior Advisor for TPG Capital and Lead Director of Immucor, Inc., a private company, wholly owned by TPG. Immucor is a market leader in helping secure the world’s blood supply through automation.
Prior to joining Immucor in 2011, Mr. Hawkins served as Chairman and CEO of Medtronic, one of the worlds’ largest and most innovative medical technology companies. Mr. Hawkins assumed the role of CEO in 2007 and became Chairman of the Board in 2008. He joined Medtronic in 2002.
Mr. Hawkins joined Medtronic from Novoste Corp., where he had been President and Chief Executive Officer since 1998. He previously held senior leadership positions at American Home Products, Johnson & Johnson, Guidant Corp., and Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.
Mr. Hawkins received his bachelor’s degree in electrical and biomedical engineering from Duke University in 1976, where he also conducted medical research in pathology. He then went on to earn an MBA from the Darden School of Business, University of Virginia in 1982. Mr. Hawkins became a member of the Duke University Board of Trustees in 2011 and serves on the Business and Finance and the Academic Affairs Committees. In 2012, he was appointed as a member of the Duke University Health System, Inc. and serves on the Audit and Compliance Committee.
Mr. Hawkins is the Chairman of MDIC and was recently elected as the 2013 President of the American Institute of Medical and Biological Engineering (AMIBE). He serves as a Director on the Board of AdvaMedDX, is the Chairman of the Board for KeraNetics, and on the Board of Thoratec Corporation, a NYSE-listed medical device company.
Mr. Hawkins also serves as a Member of the Advisory Boards at nContact Surgical, Arboretum Ventures, Radius Ventures, LLC, Accuitive Medical Ventures, and the A*STAR SERC Cluster Advisory Board in Singapore.
Mr. Hawkins and his wife, Sharon Hawkins, have three children: Elizabeth, Duke University Class of 2009; Julia, Duke University Class of 2012; and Will, Duke University Class of 2014.

 

Ross Jaffe, MD | Versant Ventures

Managing Director and Director, National Venture Capital Association (NVCA)

Ross Jaffe

Ross Jaffe is a venture capitalist who focuses on early-stage investing in medical technology.  Ross is a Managing Director of Versant Ventures, a firm he co-founded in 1999 after spending nine years at Brentwood Venture Capital where, as a general partner, he led investments in medical devices, drug delivery, and healthcare information systems companies.

During his twenty five years in venture capital, Ross has served on the boards of a number of successful life science companies, including Acclarent, St Francis Medical Technologies, Ablation Frontiers, Insulet, Therasense, and Novacept.  He currently serves on the boards of Alter-G, Cerephex, Intersection Medical, Minerva Surgical, and Sympara.

Active in the health care venture capital community, Ross serves as a Director of the National Venture Capital Association (NVCA) and as a Director of the Medical Device Innovation Consortium (MDIC), where he is the Board Champion for the Patient Centered Benefit-Risk Project.  He chairs the Board of Overseers of the Geisel School of Medicine at Dartmouth and is a member of the Board of Advisors of the Dartmouth Institute for Health Policy & Clinical Practice.

Ross is trained as an internal medicine physician, having attended medical school at Johns Hopkins and completing his residency training at the University of California, San Francisco, where he remained a part-time physician until 1995.  He also holds an MBA from Stanford.

 

Tamara Syrek Jensen, JD | Centers for Medicare & Medicaid Services (CMS)

Director, Coverage and Analysis Group (CAG)

Tamara Syrek Jensen is the acting director for the Coverage and Analysis Group (CAG) at the Centers for Medicare & Medicaid Services (CMS). CAG develops, interprets, communicates, and updates evidence based national coverage policies. These policies help provide timely access to reasonable and necessary services and technologies to improve health outcomes for Medicare beneficiaries.
 Before her current position at CAG, she was the Special Assistant for the CMS Chief Medical Officer and Director of Office of Clinical Standards and Quality (OCSQ). Prior to working at CMS, she worked as a legislative assistant in the U.S. House of Representatives. Tamara is an attorney, licensed in Maryland.

Krishna Kandarpa, MD, PhD | NIBIB, NIH

Director, Research Sciences and Strategic Directions

Most recently, he served as Chief Medical and Scientific Officer, Delcath Systems, Inc., New York, NY, developer of a combination drug/device for treating liver cancers.

He was previously Professor (Tenured) & Chair of Radiology at the University of Massachusetts Medical School and Radiologist-in-Chief, UMASS Memorial Medical Center, Worcester, MA; Professor of Radiology, Cornell Medical School, and Chief of Service, Cardiovascular & Interventional Radiology, New York-Presbyterian Hospital, New York, NY; Associate Professor of Radiology, Harvard Medical School; and co-Director, Cardiovascular & Interventional Radiology, Brigham and Women’s Hospital, Boston, MA. He received a Ph.D in Engineering Science from Pennsylvania State University and an MD from the University of Miami. He was past President and Chair of the Society of Interventional Radiology Research & Education Foundation (SIRREF) and on the Board of Directors, Academy of Radiology Research (ARR).

 

Richard E. Kuntz, MD, MSc | Medtronic, Inc.

Senior Vice President and Chief Scientific, Clinical and Regulatory Officer

Richard-KuntzDr. Rick Kuntz is Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of Medtronic, Inc. In this role, which he assumed in August 2009, Kuntz oversees the company’s global regulatory affairs, health policy and reimbursement, clinical research activities, ventures and new therapies, strategy and innovation, corporate development, and acquisitions, integrations and divestitures functions.

Kuntz joined Medtronic in October 2005 as Senior Vice President and President of Medtronic Neuromodulation, which encompasses the company’s products and therapies used in the treatment of chronic pain, movement disorders, spasticity, overactive bladder and urinary retention, benign prostatic hyperplasia, and gastroparesis. In this role he was responsible for the research, development, operations and product sales and marketing for each of these therapeutic areas worldwide.

Kuntz brings to Medtronic a broad background and expertise in many different areas of healthcare. Prior to Medtronic he was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the United States Food and Drug Administration (FDA). Kuntz has directed over 100 multicenter clinical trials and has authored more than 200 original publications. His major interests are traditional and alternative clinical trial design and biostatistics.

Kuntz also served as Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston, MA.

Kuntz graduated from Miami University, and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency in internal medicine at the University of Texas Southwestern Medical School, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Kuntz received his master’s of science in biostatistics from the Harvard School of Public Health.

 

Aran Maree, MD | Johnson & Johnson

Chief Medical Officer, Medical Devices

Aran Maree, MDDr. Aran Maree is Chief Medical Officer of the Medical Devices family of companies at Johnson & Johnson, based in New Jersey, USA. In his capacity as Chief Medical Officer, Aran leads the sector Medical Safety Organization and chairs the sector Development Committee, Medical Safety Council and Clinical Leadership Council. Aran has more than 20 years’ experience in the world of healthcare, pharmaceuticals and medical devices in Europe, the Middle East, Asia Pacific and the USA, including working at companies such as The Boston Consulting Group, Merck and Johnson & Johnson. Aran graduated with honors from the Royal College of Surgeons of Ireland and is a Member of the Royal College of Physicians in Ireland. He trained in internal medicine and interventional cardiology in Dublin, Ireland and Sydney, Australia.

 

Michael R. Minogue | Abiomed

President, CEO, and Chairman

MDIC Board Chair

Michael-MinogueMr. Michael R. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc. (NASDAQ: ABMD). Since joining in April 2004, Mr. Minogue changed the corporate strategy and mission to creating breakthrough heart support technologies for patients to enable more complete minimally invasive procedures, heart muscle recovery and cost-effective patient care. To achieve this goal, Abiomed acquired and developed new technology such as the Impella, Symphony, recovery VADs and other heart support concepts. The Impella platform is based on the world’s smallest heart pumps which can be inserted percutaneously through a small hole in the leg.

During Mr. Minogue’s tenure, Abiomed has grown more than five times in revenue and market capitalization and become GAAP profitable with no debt. Pertaining to product development, Abiomed has earned greater than 15 regulatory approvals on new products related to the CE Mark, 510(k), PMA and HDE. Prior to joining Abiomed, Mr. Minogue completed a successful 11 year career at GE Healthcare. He departed GE as the Vice President of Americas Sales and Marketing for the $1B Information Technology business. At GE, Mr. Minogue held various leadership positions in sales, marketing, service, product engineering and software development. The experience includes the diagnostics of diseases from cancer to heart failure and in various technologies such as MRI, CT, PET, X-ray, Cardiology, and Information Technology and Monitoring.

Prior to Abiomed and GE, Mr. Minogue served as an infantry officer in the U.S. Army for four years and eight years Individual Ready Reserve, which included multiple distinctions including Airborne, RANGER, Combat and Expert Infantryman’s badge, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago. Mr. Minogue holds three patents, currently serves on the executive board of directors for AdvaMed, was formerly on the board for LifeCell Corporation (LIFC), and provides personal support for organizations helping military veterans and wounded warriors.

 

William V. Murray | Medical Device Innovation Consortium (MDIC)

President and CEO

1_Bill Murray_20Aug2013Bill joined MDIC in August of 2013 as the first President and CEO. He has over 25 years of senior leadership experience spanning the range of privately financed start-up to billion dollar plus global businesses. Bill’s small company experience spans 5 years as CEO and executive consultant, including 3 years as CEO of ReShape Medical. His large company experience includes leadership as the Molecular Biology Division President of Applied Biosystems, and at Medtronic where he spent nearly 20 years in various senior leadership positions, including President of the Pacemaker Business. Bill has also served as interim President and CEO of MTS Systems (MTSC) a public $500M industrial technology company. Bill currently serves on the Boards of MDIC, ILT, Sonex Health and Meso-FLow and previously served on the Boards of MTS Systems, LifeSync Holdings, and ReShape Medical. Bill has also served on various industry association and community leadership boards. He earned a Bachelor of Science Degree in Electrical Engineering from The University of Florida.

 

Richard Naples | BD

Executive Vice President and Chief Regulatory Officer

Rick_Naples

As Executive Vice President and Chief Regulatory Officer, Rick Naples is responsible for global market access, market development and regulatory compliance functions.  This includes regulatory market authorization, postmarket compliance, public policy and reimbursement.  Rick has been with BD for a total of nine years.

Overall, Mr. Naples has over 30 years of experience in the medical technology industry. Rick and his team have lead over 300 successful FDA regulatory submissions and driving numerous industry-wide initiatives to shape healthcare policy to ensure more timely patient access to innovative new technologies.  He currently serves on the Board for the Medical Device Innovation Consortium (MDIC).  MDIC is the first public-private partnership with FDA to advance regulatory science in order to speed time to market for new medical technology.  For the last several years, he chaired the AdvaMed Diagnostics Task Force and has been recognized by the trade press as one of the top regulatory professionals in the industry.

Prior to joining BD, Rick was Roche Diagnostics VP of Regulatory and Government Affairs after serving as a Consumer Safety Officer at FDA HQ Center for Biologics, Evaluation and Research (CBER).  He has also served on the boards of the New England Healthcare Institute (NEHI) and the Indiana Medical Device Manufacturers Council (IMDMC).

Rick holds a Bachelor of Science degree in Chemistry/Medical Technology from Youngstown State University (Ohio).

 

Caroll H. Neubauer | B. Braun of America Inc. and B. Braun Medical Inc.

Chairman and CEO

Caroll H. Neubauer
Caroll Heinz Neubauer is a member of the global Management Board of the B. Braun Melsungen Group of Companies. Mr. Neubauer oversees the North America operations from Bethlehem, PA, where he serves as the Chairman and Chief Executive Officer of B. Braun of America Inc. and B. Braun Medical Inc.

Mr. Neubauer has served B. Braun for more than 25 years. In 1991, he was elected to the Management Board of B. Braun Melsungen AG and appointed General Counsel for the B. Braun group. Prior to that, he was the Head of the Legal, Security and Environmental Matters Departments for B. Braun Melsungen AG. Mr. Neubauer began his career with B. Braun in 1988 at B. Braun Melsungen AG, where he served as Legal Assistant to the Chairman of the Board and principal of the company.

Mr. Neubauer is, inter alia, currently the Chairman of the German American Chamber of Commerce New York, and a member of the Board of Directors of AdvaMed (the industrial association of medical device manufactures in the U.S.). He also serves as a member of the President’s Advisory Group of the U.S. Chamber of Commerce.

Mr. Neubauer was born in New Jersey, and completed his schooling in both the United States and Germany. He earned a German Law Degree from The Albert Ludwigs University, Freiburg, Germany in 1983. Mr. Neubauer earned his Master of Laws (LL.M.) from Georgetown University in 1987.

 

Bryan D. Olin, PhD | LivaNova

Vice President, Clinical, Quality, and Regulatory

Bryan D. Olin, PhD, joined Cyberonics as Vice President, Quality in May 2009. In August 2009, Dr. Olin assumed interim responsibility for Clinical Affairs and was named Vice President, Clinical Affairs & Quality in November 2009.  Subsequently, in April 2011, he assumed responsibility for Regulatory Affairs.  He joined Cyberonics from Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco Bay Area, where he served as Sr. Director, Quality Assurance beginning in October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis franchises of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his PhD in Statistics from Iowa State University.

 

Peter Saltonstall | National Organization for Rare Disorders (NORD)

President and CEO

Peter-SaltonstallPeter is NORD’s President and Chief Executive Officer. He has over 30 years of healthcare experience in both for-profit and not-for-profit environments, as well as extensive federal and commercial market knowledge. Peter has held senior positions within a number of major academic medical centers and organizations, including Harvard’s Brigham and Women’s Hospital, Tufts-New England Medical Center and St. Elizabeth’s Medical Center of Boston.

 

Randall Schiestl | Boston Scientific Corporation

Vice President, Global Technology

Schiestl,RandyRandall (Randy) Schiestl, PMP, is the Vice President of Global Technology at Boston Scientific, where he leads a team to deliver computational analysis, technology roadmapping, product design, packaging & labeling, knowledge management, and lab & test services. Randy’s latest role is building Global Technical Community across the corporation. He has BSME, MBA and Executive MBA degrees from the University of Minnesota. Randy received the UMAA Alumni Service Award from the College of Science & Engineering in 2011 and the Design of Medical Device Conference Award in 2012.

 

Jeffrey Shuren, MD, JD | Food and Drug Administration (FDA)

Director, Center for Devices and Radiological Health (CDRH)

Jeffrey-ShurenJeffrey Shuren became the director of the Center for Devices and Radiological Health at the Food and Drug Administration (FDA) in January 2010. He previously served as Acting Center Director, beginning in September 2009. The center is responsible for assuring the safety, effectiveness, and quality of medical devices; assuring the safety of radiation-emitting products (such as cell phones and microwave ovens); and fostering device innovation.

Jeff has held various policy and planning positions within FDA from 1998 to 2009, including acting deputy commissioner for policy, planning, and budget; associate commissioner for policy and planning; special counsel to the principal deputy commissioner; assistant commissioner for policy; and medical officer in the Office of Policy.

From 1999 to 2000, Jeff served as a detailee on the Senate Health, Education, Labor, and Pensions Committee. From 1998 to 2003, he also was a staff volunteer in the National Institutes of Health’s Cognitive Neuroscience Section, where he supervised and designed clinical studies on human reasoning.

As director of the Division of Items and Devices, Coverage and Analysis Group at the Centers for Medicare and Medicaid Services from 2001 to 2003, Jeff oversaw the development of Medicare national coverage determinations for drugs, biologics, and non-implantable devices.

Jeff received his BS and MD degrees from Northwestern University under its Honors Program in Medical Education. He completed his medical internship at Beth Israel Hospital in Boston, his neurology residency at Tufts New England Medical Center, and a fellowship in behavioral neurology and neuropsychology at the University of Florida. He received his JD from the University of Michigan.

 

Beth Staub | Stryker Corporation

Group Compliance Officer, Global Quality and Operations

Beth joined Stryker in 1989 as Quality Assurance Manager for the Orthopedics Division, and has held a series of roles in Quality, Regulatory, Clinical and Operations.  In 1999, she was promoted to VP of Quality, Regulatory and Clinical Research for the newly formed Howmedica Osteonics Corporation, and in 2007 was appointed  VP,  RAQA for Stryker Corporation, responsible for the oversight of Stryker’s quality systems, post market surveillance, product registrations, and market access activities.  In January 2017 she moved to her current role of Compliance Officer for Stryker’s Global Quality and Operation.

Prior to joining Stryker, Beth was Quality Assurance Manager for MicroScan, an In-Vitro Diagnostic Division of Baxter Healthcare with locations in California and New Jersey.  Beth holds a BS in Medical Technology from York College of Pennsylvania, and is a member or ASQ and RAPS.

 

Joseph F. Woody | Acelity

President and CEO

Joseph F. Woody
Joe Woody is President and Chief Executive Officer of Acelity, a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited.
Acelity’s innovative and complementary product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. With approximately $1.9 billion in revenue, Acelity is the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair, and the market leader in collagen dressings. Acelity products are available in more than 80 countries.
Mr. Woody joined Kinetic Concepts (KCI) in 2011 and successfully led the company’s transition from a public-to-private corporation, introduced the high performance management system across the organization and established KCI as the global leader in transformational healing solutions. Under his leadership, KCI successfully acquired Systagenix (2013) and MoMelan Technologies (2012), which led to fast-tracking the launch of the innovative CelluTome™ Epidermal Harvesting System (2013). In 2014, Mr. Woody led efforts to integrate KCI, LifeCell and Systagenix into Acelity, a global corporation devoted to advancing the science of healing.
With more than 20 years of experience in the healthcare sector, Mr. Woody held key executive roles at a number of industry-leading medical technology companies both in the US and Europe. Prior to his role at Acelity, Mr. Woody served as Global President, Vascular Therapies for Covidien, where he was responsible for the $2.6 billion acquisition and integration of ev3, a peripheral vascular and neurovascular business. He has also served in sales and executive leadership positions at Smith & Nephew, Alliance Imaging, Inc., Acuson and GE Medical Systems.
Mr. Woody serves on the Board of Directors of the Advanced Medical Technology Association (AdvaMed) and is Chair of the Wound Healing and Tissue Regeneration Sector. At present, he serves on the board of Acelity L.P. Inc. and was previously a board member at Systagenix. He is also dedicated to giving back to the communities in which Acelity employees live and work through volunteerism and philanthropy.
Mr. Woody holds a Bachelor’s degree from California State University, Fullerton.

 

Nadim Yared | CVRx

President and CEO

Nadim-YaredMr. Nadim Yared has been the President and Chief Executive Officer of CVRx Inc. since October 4, 2006. Mr. Yared served as Vice President and General Manager of Medtronic Navigation (formerly Medtronic, Inc.), the leading supplier of integrated image-guided surgery products in the world from 2002 to 2006. He joined Medtronic Navigation in 2002 after a 10-year career with GE Medical, where he held engineering and marketing management positions of increasing responsibility, including Vice President and General Manager of GE’s European X-ray business. He served as Vice President of Global Marketing for the OEC Medical Systems. He has been Director of Hansen Medical, Inc. since July 2012. He serves as Director of AdvaMed, and Intio, a privately-held interventional oncology company. He serves as a Director of CVRx Inc. Mr. Yared received an engineering degree from Ecole Nationale Superieure des Télécommunications and an MBA degree from INSEAD in Paris.